SEI Investments
BOLD

SEI Investments’s Audentes Therapeutics, Inc BOLD Stock Holding History

SEI Investments’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-800
Closed -$31K – 3722
2018
Q2 		$31K Hold
800
– – ﹤0.01% 2660
2018
Q1 		$24K Buy
+800
New +$27.1K ﹤0.01% 2602

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SEI Investments's BOLD Position: Q3 2018 in Review

SEI Investments sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2018, closing a stake of 800 shares — an estimated $31K sold.

SEI Investments first reported a position in BOLD in Q1 2018 and held it in 2 quarters. The position peaked at $31K in Q2 2018. 114 funds tracked by Wall St. Rank hold BOLD as of Q3 2018.

  • SEI Investments reported no remaining Audentes Therapeutics, Inc position as of Q3 2018 after selling out during the quarter.
  • SEI Investments sold 800 Audentes Therapeutics, Inc shares in Q3 2018, an estimated $31K.
  • SEI Investments first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 2 quarters.
  • SEI Investments's Audentes Therapeutics, Inc position peaked at $31K in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2018.

Based on SEI Investments's 13F filing for Q3 2018, filed 8 Nov 2018.